ClinicalTrials.gg
Not yet recruitingNCT07792811NIMBUSUpdated Aug 28, 2026

Non-Invasive Deep Brain Stimulation for Upper Limb Recovery After Stroke (NIMBUS)

A Phase 2/3 interventional study of Non-invasive transcranial Temporal Interference Stimulation (iTBS-tTIS Striatum) and Concurrent Intensive Motor Rehabilitation in Stroke and Stroke Assessment, sponsored by Friedhelm Hummel. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Friedhelm Hummel · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 216 studies in Stroke with a site in Switzerland — 46 open to participants now, 60 under way, 6 of them phase 3. Stroke · Switzerland.

Planned enrollment
70th of 147
84 · median 79
Started
2026
with 11 others
Phase 2/3
3 of 216
1 open now
Primary completion
2029-12
later than 51 of 59 live
Registered
215th of 216
by date

Among the 216 studies in Stroke with a site in Switzerland, this one is the 70th largest by planned enrollment of the 147 interventional ones that give a count, is one of 12 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 51 of the 59 other live ones, and was the 215th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

46 of the 216 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Stroke with a site in Switzerland, or all of them as a file.
02

Study summary

NIMBUS is a clinical study evaluating a new, non-invasive brain stimulation treatment to improve arm and hand function in people with long-term effects of stroke. The treatment uses a personalized method to stimulate deeper areas of the brain through the scalp, without surgery, while participants undergo intensive physiotherapy rehabilitation. Physiotherapy in combination with the brain stimulation will occur three times a day over the course of a week. In the study, participants are randomly assigned to receive either the active treatment or a sham (inactive) version, so researchers can compare the outcomes fairly. The study will assess whether the treatment is safe, feasible, and effective by measuring changes in arm movement, daily activities, and brain function before and after the treatment. The goal is to determine whether this approach can enhance recovery after stroke and support the development of improved rehabilitation therapies.

Read the detailed description
  • The burden of stroke.** Stroke is a major cause of acquired disabilities, with a growing number of survivors due to an aging society and improved acute management. Still, persistent motor impairment is highly common in stroke patients and is associated with a poor level of reintegration in normal life. Effective novel neurorehabilitation strategies are thus urgently required to enhance recovery rates and decrease the burden of stroke for patients, the healthcare systems and society.
  • Neuroplasticity and brain networks.** To improve the efficacy of therapeutic strategies for stroke patients, a clear understanding of the neuronal mechanisms underlying post-stroke recovery is essential. Stroke lesions initiate a cascade of changes in brain metabolism, functional activation, neuronal excitability, and structural integrity. Recent neuroimaging studies, including structural and functional analyses, have highlighted dynamic network changes that are particularly important in the process of successful recovery. For upper extremity (UE) motor function, the recovery network notably includes the primary and secondary motor cortices, as well as core deep brain structures such as the striatum. Neuroplastic changes in these areas are critical elements for successful functional reorganization and recovery after a stroke. An important aspect is the enhanced plasticity observed during the acute and subacute phases after a stroke-specifically, the first 12 weeks, known as the "hyper-plastic phase." This period corresponds to a sensitive window during which the brain responds optimally to external stimuli, activity, rehabilitative treatments, and interventional strategies. Intensive interventional approaches during this time are most effective in promoting brain plasticity and recovery. However, spontaneous brain reorganization after a stroke often fails to achieve substantial and satisfactory functional recovery independently.
  • Promising but unsatisfactory results from NIBS.** Among various innovative neurorehabilitation strategies, non-invasive brain stimulation (NIBS) is associated with promising results to neuromodulate brain activity and enhance neuroplasticity and motor recovery by potentiating the response to behavioural training. The safe and easy application of NIBS makes the technique particularly interesting for clinicians and scientists. However, despite this exciting potential, the application is so far limited to cortical areas (e.g., motor cortex) and has revealed heterogeneous results regarding motor recovery. This heterogeneity might be due to the so far 'one suits all non-personalized' application of NIBS. Historically, the motor cortex has been the primary target for interventions, despite the possibility that the motor cortex may not be as crucial as other brain regions in motor skill acquisition and consolidation-key components of neurorehabilitation and recovery. However, core deep brain structures, such as the basal ganglia, particularly the striatum, which are critically involved in (re-)learning, reorganization, and recovery processes after stroke, have remained inaccessible to non-invasive interventions.
  • Role of the basal ganglia/striatum under physiological conditions.** Deep subcortical structures such as the basal ganglia are relay nodes representing a critical hub in the motor network. In particular, the striatum plays a substantial role in key aspects of sensorimotor processing and learning, essentially important for the execution and (re-)acquisition of motor skills. Lesion studies in animal models demonstrated the significant role of the striatum in the acquisition and the retention of motor behavior. For example, lesions of the dorsal striatum in primates resulted in significant motor impairment, e.g., slowness of movement and altered acquisition of motor skills while lesions of the dorsolateral striatum in rats led to the disruption of motor habit formation. In humans, the classical studies of patients with neurological disorders affecting the striatum (as Parkinson's Disease) demonstrated striatal involvement not only in movement performance but also in the acquisition of new motor skills. This was further underlined in non-human primate models of Parkinsonism. Furthermore, imaging data were able to delineate the involvement of basal ganglia in the motor learning network in healthy humans.

In sum, the striatum is a key structure of motor control and (re-)learning. The striatum contributes to multiple levels including initiation of movements, facilitation of goal-directed actions, habit formation and especially motor skill acquisition, consolidation and retention. This makes the striatum a very promising target for interventional strategies based on striatal neuromodulation combined with motor (re-)learning after brain lesions. This concept is further supported by current evidence that the striatum is a highly neuroplastic area given the striatum's composition and known associations with critical neurotransmitter systems.

  • Striatum in stroke - animal and human models.** Emerging evidence from both animal and human studies underscores the pivotal role of the striatum in post-stroke recovery mechanisms, highlighting the striatum as a promising target for neuromodulation therapies. In animal stroke models, a consistent regenerative response has been observed after focal strokes, resulting in the replacement of lost striatal neurons. Despite disturbances in movement-related neuronal activity following motor cortical strokes, the striatum continues to play a substantial role in controlling residual motor functions. During rehabilitation, reorganization of striatal activity strongly correlates with improvements in animals' motor abilities. Moreover, optogenetic stimulation of striatal activity promotes neurogenesis and long-term functional recovery, demonstrating a causal relationship between striatal activity and motor function restoration. In human studies, neuroimaging has revealed that lesions in the basal ganglia are associated with abnormal interaction patterns with cortical areas after a stroke. Structural connectivity with the basal ganglia two weeks post-stroke significantly contributes to predicting motor recovery at three months. A large-scale study involving over 800 individuals found that reduced volume of the ipsilesional striatum is strongly associated with poorer outcomes in the chronic phase. Collectively, these findings suggest that neuroplastic changes in the striatum are crucial for supporting motor recovery. Interestingly, the striatum is also involved in reward processing and motivation as well as visuospatial attention-aspects that play significant roles in the relearning and reacquisition of motor skills following a stroke. Deficits in reward processing among stroke patients have been linked to reduced activity in the ventral striatum, independent of structural damage. Furthermore, individuals with lesions in the basal ganglia exhibit poorer reward sensitivity, higher levels of apathy, and impaired visuospatial attention. Therefore, the basal ganglia, particularly the striatum, serve as key nodes within brain networks that facilitate motor recovery and influence critical aspects of motor skill reacquisition-such as reward, motivation, and attention-which are fundamental mechanisms underpinning neurorehabilitation.
  • Striatum and LTP-like plasticity.** Approximately 95% of striatal cells are GABAergic medium spiny neurons (MSNs), which receive glutamatergic inputs from the cortex and dopaminergic inputs from the substantia nigra. MSNs have the capacity to undergo long-term potentiation (LTP) or long-term depression (LTD)-key neuroplasticity mechanisms-in response to high-frequency stimulation. Theta burst stimulation, initially demonstrated in hippocampal slices, can induce LTP- and LTD-like plasticity in the striatum, particularly when delivered in patterns that mirror natural striatal activation. This underscores the significance of activity-dependent effects linked to physiological striatal firing in enhancing behavioral outcomes. Importantly, LTP at corticostriatal synapses is associated with motor behavior and may constitute a key cellular substrate for motor learning and skill acquisition. These attributes make the striatum an excellent target for neuromodulatory interventions, especially for LTP-inducing theta-burst stimulation. Collectively, this evidence reinforces the view that the striatum is a highly neuroplastic structure playing a crucial role in motor skill acquisition-two essential aspects for functional reorganization and motor recovery after stroke.
  • Transcranial temporal interference stimulation (tTIS).** The aforementioned animal and human studies have highlighted the critical role of the striatum in motor learning, recovery processes, and neuroplasticity. These findings strongly support the striatum as a novel, promising target for neuromodulation-based interventions to effectively support recovery, particularly during the subacute, hyperplastic phase following a stroke. However, traditional NIBS techniques, such as transcranial direct current stimulation (tDCS), alternating current stimulation (tACS), and transcranial magnetic stimulation (TMS), are unable to reach deep brain structures like the striatum due to the inherent trade-off between focality and depth. The recent introduction of transcranial temporal interference stimulation (tTIS) presents an exciting, implementable, and promising non-invasive approach. tTIS enables targeted, non-invasive modulation of striatal activity with an excellent balance between depth and focality. Striatal tTIS represents a groundbreaking, novel interventional strategy to enhance motor recovery following brain injury.

In first-in-human proof-of-concept studies, **the investigators demonstrated** that striatal neuromodulation by tTIS is feasible and safe. Applying theta burst patterned tTIS (iTBS-tTIS) to the striatum led to a significant, improvement in motor skill acquisition and increased activity changes in the striatum and the connected network. The behavioral improvement was most pronounced in healthy old adults, typically in comparable age as stroke patients. Additional proof-of-concept studies further support the feasibility and efficacy of tTIS in brain lesioned patient cohorts. For instance, **the investigators conducted** a study involving 15 patients with traumatic brain injury (TBI) and, demonstrating that tTIS significantly improved motor learning and retention, with clinically meaningful effects observed for at least 24 hours after stimulation. Moreover, a study in patients with Parkinson's disease demonstrated that tTIS can improve motor symptoms, particularly bradykinesia and tremor. Collectively, these results highlight that tTIS is a safe and well-tolerated technique, demonstrating strong potential for improving motor outcomes in various neurological conditions. To achieve not only the demonstrated shorter-lasting, but long-lasting effects in the present project, **the investigators will significantly enhance the dosage and apply an accelerated stimulation protocol with three stimulation sessions per day for one week.**

  • Accelerated stimulation protocols for neurorehabilitation.** Recent clinical guidelines from leading organizations such as the National Institute for Health and Care Excellence (NICE), the Intercollegiate Stroke Working Party (ISWP), and the European Stroke Organisation (ESO) emphasize the critical importance of increasing the intensity of upper limb motor rehabilitation in stroke recovery. Accelerated protocols-entailing multiple therapy sessions per day-have emerged as an effective strategy to significantly enhance functional outcomes and improve the quality of life for stroke survivors. Studies have highlighted the benefits and safety of accelerated brain stimulation protocols across various conditions, including stroke, depression, Parkinson's disease and Alzheimer's disease. These protocols, which deliver multiple stimulation sessions per day over consecutive days, have demonstrated equal or greater effectiveness compared to traditional, longer treatment paradigms. Moreover, accelerated protocols reduce the overall time commitment for patients, minimizing the impact on **patients' professional responsibilities and transportation demands**. Building on this evidence, **the investigators propose** to implement an accelerated striatal tTIS protocol, aiming to achieve more rapid, intensive, and effective motor rehabilitation.
  • Primary research question.** Current evidence highlights that (a) the striatum is a core structure involved in post-stroke motor recovery, and (b) there is an innovative opportunity to neuromodulate the striatum non-invasively, safely, and with precise depth-focality. This breakthrough could pave the way for novel and disruptive treatment strategies to enhance stroke recovery. **The investigators hypothesize** that personalized, accelerated striatal tTIS, combined with upper extremity rehabilitative training, will be feasible, safe, and lead to greater behavioral improvement and recovery than placebo stimulation with rehabilitative training in chronic stroke patients. The primary endpoints are composite upper extremity motor functions, feasibility and safety. To test this hypothesis, **the investigators will conduct** a double-blind, placebo-controlled, multicenter clinical trial. **The investigators will apply** intermittent theta-burst tTIS to the striatum (iTBS-tTISStriatum), with individualized electrode positioning based on each patient's anatomy, alongside intensive rehabilitation therapy. This will be the first clinical trial to non-invasively target deep brain structures (striatum) to enhance stroke recovery in humans.

**Secondary research questions.** The core aspect of the present project is to determine the behavioral effects of the suggested transformative interventional strategy on motor recovery. However, **the present project also requires personalized electrode placement and assessment of the impact of the intervention on daily life activities, higher order cognitive functions, brain activity and long-term effects. The project should further allow evaluation of factors that impact the degree of individual treatment response, paving the way to biomarkers.**

  • Changes in daily life-oriented behavior - the Smart Kitchen Assessment:.** Therapy-induced changes in functional upper-limb performance in daily-life-like tasks will be quantified using objective, instrumented measures before (week 1) and after (week 3) the therapy. The outcomes will include: change in movement speed and smoothness of the paretic upper limb, change in movement efficiency during functional tasks, change in bimanual coordination, change in task success rate. These outcomes reflect clinically meaningful improvements in dexterity and functional task performance in an ecologically valid environment, and enable the discrimination between true motor improvement and compensatory strategies.
  • Changes in daily life-oriented behavior - Questionnaires.** Changes in daily functioning and perceived health will be evaluated from before the therapy (week 1) to after the therapy (week 3) using validated clinical questionnaires and observation scales. Outcomes will include: change in independence in activities of daily living, change in upper-limb performance during daily activities, change in patient-reported global health and well-being.

**Treatment-induced changes in sensory, psycho-social and cognitive domains.**

Non-motor effects of the therapy will be assessed through changes from before (week 1) to after (week 3) the intervention in: mood and motivation, fatigue and sleep quality, sensory function, attention, executive functions, and spatial awareness. These outcomes provide a concise characterization of therapy-related changes beyond motor performance.

**Treatment-induced changes in network properties (Multi-modal MRI and electrophysiology).**

Neurobiological effects of the therapy will be evaluated through changes in: structural and functional brain connectivity, global network efficiency and integration, cortical excitability and excitation-inhibition balance. These outcomes will support interpretation of clinical effects and mechanisms of recovery.

**Long-lasting treatment-induced changes in behavior:** To determine whether the achieved effects of the proposed interventional strategy persist, **the investigators will invite the patients** for a clinical, behavioral follow-up evaluation (FU) 3 months after the end of the treatment. Outcomes of interest will be similar to the primary outcomes, and to those established to assess changes in daily-life behavior (questionnaires and Smart Kitchen assessment) and in sensory, psycho-social, and cognitive domains.

03

Conditions studied

  • Stroke
  • Stroke Assessment

Browse trials for

Keywords

  • Stroke Rehabilitation
  • Upper Extremity Motor Recovery
  • Noninvasive Brain Stimulation
  • Transcranial electrical temporal interference stimulation (tTIS)
  • Neuroplasticity
  • Personalized medicine
  • Randomized controlled trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. signed by the participant
  2. Age ≥ 18 years old
  3. First ever ischemic stroke with motor impairment
  4. Stroke incident ≥ 12 weeks at consent
  5. Moderate to severe motor impairment (Fugl-Meyer Assessment (FMA) >20 and \<58)

Exclusion criteria

Exclusion Criteria:

  1. Unable to provide due to cognitive, psychiatric, or medical conditions impairing decision-making capacity
  2. Severe neuropsychiatric (e.g., major depression, schizophrenia) or medical disease (e.g., progressive cancer, unstable systemic disease, neurodegenerative disease)
  3. Severe cognitive, sensory or musculoskeletal dysfunctions prohibiting to understand instructions or to perform the rehabilitative tasks
  4. for NIBS or MRI

    a. Electronic or ferromagnetic medical implants/device, non-MRI compatible metal implant, b. Fully or partially implanted conductive objects i. Passive implants: stents, orthopedic/orthodontic implants, screws, shunts, etc.

    ii. Active implants: cochlear implants, deep brain stimulation leads and electrodes, fully implanted brain monitoring devices iii. Partially implanted devices: monitoring electrodes (e.g., stereoelectroencephalography, electrocortigraphy, etc.

    iv. Surface-mounted conductive objects: conductive low-impedance structure mounted to the skin that may introduce shortcuts.

    c. History of seizures d. Medication that significantly interacts with NIBS being benzodiazepines, tricyclic antidepressants and antipsychotics.

    e. Non-intact skin where electrodes are intended ot be placed

  5. Pregnancy
  6. Regular use of narcotic drugs or abusive alcohol consumption
  7. Integral and bilateral lesion of the striatum
  8. Concomittant participation in another clinical trial
  9. Active request of not being informed in case of incidental findings
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Experimental: Active iTBS-tTIS Striatum + Rehabilitation

    Participants receive personalized, non-invasive deep brain stimulation targeting the striatum using transcranial electrical temporal interference stimulation (tTIS) combined with intermittent theta-burst stimulation (iTBS). Stimulation is delivered via individually positioned electrodes based on each participant's brain anatomy, concurrently with intensive upper-limb rehabilitation training (3 sessions per day for 1 week).

    Device: Non-invasive transcranial Temporal Interference Stimulation (iTBS-tTIS Striatum) · Behavioral: Concurrent Intensive Motor Rehabilitation

  • Active comparator
    Active Comparator: Sham tTIS Striatum + Rehabilitation

    Participants receive sham (inactive) transcranial electrical temporal interference stimulation targeting the striatum, delivered with identical setup and procedures as the active condition but without effective stimulation. This is combined with the same intensive upper-limb rehabilitation training protocol (3 sessions per day for 1 week).

    Behavioral: Concurrent Intensive Motor Rehabilitation · Device: Non-invasive transcranial Temporal Interference Stimulation sham-tTIS Striatum)

Interventions

  • DeviceNon-invasive transcranial Temporal Interference Stimulation (iTBS-tTIS Striatum)

    Transcranial Temporal Interference Stimulation (tTIS) is a non-invasive neuromodulation technique that applies multiple high-frequency electrical currents via scalp electrodes to generate an amplitude-modulated electric field in deep brain regions without surgery. The technique allows targeting of different deep brain structures depending on electrode configuration and current parameters. In this study, stimulation is individualized to target the striatum using subject-specific electrode placement based on anatomical information. The stimulation is delivered in a theta-burst-patterned protocol designed to induce plasticity-related effects. tTIS is applied concurrently with upper-limb rehabilitative training during each session. The intervention is administered over five consecutive days, with three sessions per day within an accelerated protocol.

  • BehavioralConcurrent Intensive Motor Rehabilitation

    Participants undergo intensive, task-oriented upper-limb rehabilitation training focused on improving motor function of the affected arm and hand following stroke. Training is delivered in a structured and personalized manner, adapted to the participant's level of impairment and functional capacity. Each session includes approximately 30 minutes of physiotherapy involving repetitive, goal-directed movements and functional tasks targeting upper-limb use. The rehabilitation is provided concurrently with stimulation (active or sham) and follows an accelerated schedule of three sessions per day over five consecutive days.

  • DeviceNon-invasive transcranial Temporal Interference Stimulation sham-tTIS Striatum)

    Sham Transcranial Temporal Interference Stimulation (tTIS) is a non-invasive neuromodulation procedure that applies two identical high-frequency electrical currents via scalp electrodes. Because the currents have the same frequency, no low-frequency amplitude-modulated electric field is generated in deep brain regions. The sham stimulation uses the same individualized electrode placement based on anatomical information and follows the same stimulation schedule and device settings as the active intervention, while not delivering the temporal interference pattern intended to modulate striatal activity. Sham tTIS is applied concurrently with upper-limb rehabilitative training during each session. The intervention is administered over five consecutive days, with three sessions per day within an accelerated protocol.

06

What researchers measure

Primary outcomes

  1. Change in Upper-Limb Motor Function (Composite Motor Score)

    Upper-limb motor performance assessed using a composite motor score including the Fugl-Meyer Assessment Upper Limb, Pinch \& Grip, Box\&Blocks, Nine-Hole Peg Test, and Action Research Arm Test (ARAT). The primary endpoint is defined as the change from baseline to post-intervention.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

Secondary outcomes

  1. Change in Barthel Index Score

    Independence in basic activities of daily living will be assessed using the Barthel Index. The instrument evaluates feeding, bathing, grooming, dressing, bowel and bladder control, toilet use, transfers, mobility, and stair use. The total score ranges from 0 to 100, with higher scores indicating greater independence. The outcome will be the change in total score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  2. Changes in daily life-oriented behavior - Questionnaires.

    Changes in daily functioning and perceived health will be evaluated from before the therapy (week 1) to after the therapy (week 3) using validated clinical questionnaires and observation scales. Outcomes will include: change in independence in activities of daily living, change in upper-limb performance during daily activities, change in patient-reported global health and well-being.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  3. Change in Modified Rankin Scale Score

    Global disability will be assessed using the Modified Rankin Scale. Scores range from 0 to 5 in the study CRF, with 0 indicating no symptoms and 5 indicating severe disability requiring constant nursing care and attention. The outcome will be the change in score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  4. Change in Functional Independence Measure Total Score

    Functional independence will be assessed using the Functional Independence Measure (FIM), covering self-care, sphincter control, transfers, locomotion, communication, and social cognition. Individual items are rated from 1 (total assistance) to 7 (complete independence), and the total FIM score will be used as the outcome measure. Higher scores indicate greater functional independence. The outcome will be the change in total score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1) and post-intervention (Week 3, ±3 days)

  5. Change in Modified Upper Limb Lucerne ICF-Based Multidisciplinary Observation Scale Score

    Daily-life upper-limb function will be assessed using the Modified Upper Limb Lucerne ICF-Based Multidisciplinary Observation Scale (LIMOS). The scale evaluates lifting and carrying objects, fine hand use, hand and arm use, washing, and dressing. The summed score ranges from 0 to 20, with higher scores indicating greater independence in upper-limb-related activities. The outcome will be the change in total score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  6. Change in PROMIS Global Health Score

    Patient-reported global physical, mental, and social health will be assessed using the PROMIS Global Health questionnaire. Scores will be calculated according to the standardized PROMIS scoring procedure, with higher scores indicating better self-reported health. The outcome will be the change in score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  7. Change in Hospital Anxiety and Depression Scale - Anxiety Subscale Score

    Anxiety symptoms will be assessed using the Anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). The subscale consists of 7 items scored from 0 to 3, yielding a total score from 0 to 21. Higher scores indicate greater anxiety symptom severity. The outcome will be the change in HADS-A score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  8. Change in Hospital Anxiety and Depression Scale - Depression Subscale Score

    Depressive symptoms will be assessed using the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). The subscale consists of 7 items scored from 0 to 3, yielding a total score from 0 to 21. Higher scores indicate greater depressive symptom severity. The outcome will be the change in HADS-D score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  9. Change in State-Trait Anxiety Inventory - State Anxiety Score

    Current anxiety will be assessed using the State subscale of the State-Trait Anxiety Inventory (STAI-S). The STAI-S consists of 20 items assessing anxiety experienced at the time of assessment. The total score ranges from 20 to 80, with higher scores indicating greater state anxiety. The outcome will be the change in total score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  10. Change in State-Trait Anxiety Inventory - Trait Anxiety Score

    General anxiety tendency will be assessed using the Trait subscale of the State-Trait Anxiety Inventory (STAI-T). The STAI-T consists of 20 items and yields a total score ranging from 20 to 80, with higher scores indicating greater trait anxiety. The outcome will be the change in total score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  11. Change in Multidimensional Fatigue Inventory Score

    Fatigue will be assessed using the Multidimensional Fatigue Inventory. The questionnaire contains 20 items rated on a 5-point response scale and assesses general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. Scores will be calculated according to the standardized scoring procedure, with higher scores indicating greater fatigue. The outcome will be the change in fatigue score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  12. Change in Pittsburgh Sleep Quality Index Global Score

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The PSQI assesses sleep quality and disturbances during the preceding month and generates a global score ranging from 0 to 21. Higher scores indicate poorer sleep quality. The outcome will be the change in global PSQI score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  13. Change in Apathy Evaluation Scale Self-Rated Score

    Motivation and apathy will be assessed using the self-rated Apathy Evaluation Scale. The instrument contains 18 items assessing interest, initiative, engagement, and motivation. The total score will be calculated according to the standardized scoring procedure, with higher scores indicating greater apathy. The outcome will be the change in total score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  14. Change in Revised Nottingham Sensory Assessment Score

    Somatosensory function will be assessed using the Revised Nottingham Sensory Assessment. The assessment evaluates tactile sensation, proprioception, and stereognosis. Sensory responses are scored according to the standardized assessment criteria, with higher scores reflecting better sensory function. The outcome will be the change in sensory performance from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  15. Change in Sensitive Neglect Test Single-Task Total Omissions

    Spatial attention will be assessed using the single-task condition of the Sensitive Neglect Test (SNT). The outcome measure will be the total number of omitted targets. Higher numbers of omissions indicate greater impairment of visuospatial attention. The outcome will be the change in total omissions from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  16. Change in Sensitive Neglect Test Dual-Task Total Omissions

    Spatial attention under dual-task conditions will be assessed using the dual-task condition of the Sensitive Neglect Test (SNT). The outcome measure will be the total number of omitted targets. Higher numbers of omissions indicate greater impairment of visuospatial attention under dual-task conditions. The outcome will be the change in total omissions from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  17. Change in Long-Line Bisection Error

    Visuospatial attention will be assessed using a line-bisection task. Participants bisect two 20-cm horizontal lines, and the deviation from the true midpoint is measured in millimeters. Deviations to the right of the midpoint are recorded as positive values and deviations to the left as negative values. The mean deviation across the two 20-cm lines will be used as the outcome measure. Values closer to zero indicate more accurate spatial midpoint estimation.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  18. Change in TAP Phasic Alertness Index

    Phasic alertness will be assessed using the alertness module of the Test of Attentional Performance (TAP). Median reaction time is measured in conditions with and without an auditory warning signal. The phasic alertness index is calculated as the difference between median reaction time without and with the warning signal, divided by the overall median reaction time. The outcome will be the change in the phasic alertness index from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  19. Change in Color Trails Test Interference Index

    Divided attention and cognitive flexibility will be assessed using the Color Trails Test. Performance time and errors are recorded for Parts 1 and 2, and an interference index is derived from performance across the two parts. The outcome will be the change in the Color Trails Test interference index from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  20. Change in Stroop Victoria Test Interference Index

    Inhibitory control will be assessed using the Stroop Victoria Test. Completion times are recorded for the Color, Word, and Interference cards. The primary Stroop outcome will be the interference index calculated as completion time for the Interference Card divided by completion time for the Color Card. The outcome will be the change in the interference index from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  21. Change in Five-Point Test Correct Designs

    Nonverbal executive functioning and design fluency will be assessed using the Five-Point Test. The outcome measure will be the number of correct unique designs produced within the standardized task period. Higher values indicate greater design fluency. The outcome will be the change in the number of correct designs from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  22. Change in Phonological Verbal Fluency Score

    Phonological verbal fluency will be assessed by asking participants to generate words beginning with a specified letter during a 1-minute period. Repetitions and errors will be excluded. The outcome measure will be the number of correct words generated, with higher values indicating better verbal fluency. The outcome will be the change from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  23. Change in Digit Span Forward Total Score

    Auditory attention and short-term verbal memory will be assessed using the Digit Span Forward condition. The outcome will be the total number of correctly completed sequences according to the study scoring procedure. Higher scores indicate better performance. The outcome will be the change from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  24. Change in Digit Span Backward Total Score

    Verbal working memory will be assessed using the Digit Span Backward condition. The outcome will be the total number of correctly completed sequences according to the study scoring procedure. Higher scores indicate better working-memory performance. The outcome will be the change from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  25. Change in Digit Span Sequencing Total Score

    Working-memory manipulation will be assessed using the Digit Span Sequencing condition. Participants reproduce orally presented digit sequences in ascending numerical order. The outcome will be the total score according to the study scoring procedure, with higher scores indicating better performance. The outcome will be the change from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  26. Change in Token Test Total Score

    Auditory language comprehension will be assessed using the Token Test. Participants execute increasingly complex verbal commands using colored geometric tokens. Responses are scored according to the study scoring procedure, yielding a maximum total score of 36. Higher scores indicate better auditory comprehension. The outcome will be the change in total score from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  27. Change in Paretic Upper-Limb Movement Speed During the Smart Kitchen Assessment

    Upper-limb movement speed during standardized daily-life-like tasks in the Smart Kitchen Assessment will be quantified using instrumented movement recordings. Movement speed will be calculated as the time to complete each subtask and reported in seconds. The outcome will be the change from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  28. Change in Paretic Upper-Limb Movement Smoothness During the Smart Kitchen Assessment

    Movement smoothness of the paretic upper limb during standardized daily-life-like tasks will be quantified using tortuosity of the active wrist in linear movements (such as reaching or placing) and cycle consistency in periodic movements (such as peeling or grating). Both measures are dimensionless. Lower values of Tortuosity and Higher values of cycle consistency indicate smoother movement. The outcome will be the change from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  29. Change in Movement Efficiency During the Smart Kitchen Assessment

    Movement efficiency during standardized Smart Kitchen tasks will be quantified using using the jerk of the upper limb kinematics and reported in m/s\^3. Lower values indicate greater movement efficiency. The outcome will be the change from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  30. Change in Bimanual Coordination During the Smart Kitchen Assessment

    Bimanual coordination during standardized Smart Kitchen tasks will be quantified using using the time needed to perform bimanual tasks and reported in seconds. Lower values indicate better bimanual coordination. The outcome will be the change from baseline to post-intervention and follow-up.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days), and follow-up (Week 14, ±10 days)

  31. Change in Static Resting-State Functional Connectivity Measured With fMRI

    Static resting-state functional connectivity will be assessed using functional MRI and quantified from the temporal correlation of resting-state BOLD signals between brain regions. Correlation-based connectivity values will be used to characterize functional coupling within and between brain networks. The outcome will assess changes in static functional connectivity from baseline to post-intervention.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days)

  32. Change in Dynamic Resting-State Functional Connectivity Measured With fMRI

    Dynamic resting-state functional connectivity will be assessed using functional MRI by quantifying temporal variability in functional coupling between brain regions. Dynamic connectivity will be characterized using the variability of time-resolved functional connections, expressed as the standard deviation of connectivity-related time series. The outcome will assess changes in dynamic functional connectivity from baseline to post-intervention.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days)

  33. Association Between Structural Connectivity and Treatment Response

    Structural brain connectivity will be assessed at baseline and post-intervention using diffusion-weighted MRI and quantified using streamline-based connectivity between brain regions. Structural connectivity measures will characterize the strength or preservation of anatomical connections and will be examined for association with the magnitude of behavioral response to the intervention.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days)

  34. Change in Resting-State EEG Functional Connectivity

    Resting-state EEG will be recorded under standardized eyes-open and/or eyes-closed conditions. Functional connectivity will be quantified using Debiased Weighted Phase Lag Index (dwPLI) within the oscillatory bands of interest. The outcome will be the change in dwPLI from baseline to post-intervention.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days)

  35. Change in Cortical Excitability Measured With TMS-EEG

    Cortical excitability will be assessed using TMS combined with EEG. The outcome measure will be TEP amplitude at predefined components, electrodes, and time intervals, reported in mV. The outcome will be the change from baseline to post-intervention.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days)

  36. Change in Excitation-Inhibition Balance Measured With TMS-EEG

    Cortical excitation-inhibition balance will be assessed using TMS-EEG and quantified using the amplitude of induced TEPs in response to Paired-pulse Short intracortical inhibition (SICI) and intracortical facilitation (ICF). The measure will be reported in mV. The outcome will be the change in waveform from baseline to post-intervention.

    Time frame: Baseline (Week 1), post-intervention (Week 3, ±3 days)

  37. Incidence of Adverse Events, Serious Adverse Events, Adverse Device Effects, and Device Deficiencies

    Safety will be assessed by recording adverse events, serious adverse events, anticipated and unanticipated adverse device effects, and device deficiencies occurring during the intervention period. The number and proportion of participants experiencing each category of event will be reported together with event type and severity.

    Time frame: From the first intervention session through completion of the intervention period at the end of Week 2

07

Study locations

1 site
  • CRR SUVA
    Sion, Valais 1951, Switzerland
    • Caroline Magnin · Contactcaroline.magnin@epfl.ch
    • Maria Iakova, Dr. · Principal investigator
    • Adrian Guggisberg, Prof. Dr. · Principal investigator
    • Thomas Nyffeler, Prof. Dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — De-identified individual participant data underlying the results reported in this study, including demographic, clinical, behavioral, kinematic, neuroimaging, and electrophysiological data, will be shared. The study protocol, statistical analysis plan, and analytic code will also be made available. Data will become available beginning 6 months after publication of the primary results and will remain available for at least 5 years. Access will be granted to researchers who provide a methodologically sound proposal, for the purpose of achieving the aims outlined in the approved proposal. Data will be shared upon reasonable request to the Sponsor-Investigator, subject to review and approval of the request and the execution of a data sharing agreement, in accordance with applicable data protection regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2029, 39 months later.

Of 27 phase 2/3 interventional studies under Stroke, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's planned 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 28, 2026
StartEst.
Sep 13, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2030
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07792811
Lead sponsor
Friedhelm Hummel
Collaborators
Luzerner Kantonsspital, Hôpitaux Universitaires Genève
Responsible party
Friedhelm Hummel (Full Professor, Director Defitech Chair of Clinical Neuroengineering, Ecole Polytechnique Fédérale de Lausanne) — Sponsor-investigator
First posted
Aug 28, 2026
Start date
Sep 13, 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Aug 28, 2026

Study contacts

Jasmina P. Paneva, Dr.
Contact
jasmina.paneva@epfl.ch
+41772652660
Camille Proulx, Dr.
Contact
camille.proulx@epfl.ch
Friedhelm C. Hummel, Prof. Dr.
principal investigator · Ecole Polytechnique Fédérale de Lausanne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion